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1. Introduction
The condition of an erythrocyte could be able to affect the internal and 
external conditions of all the vital and non-vital organs of a human body. These 
little biconcave disk-shaped red structures of approximately 8 μm in diameter and 
of about 2.5 μm in thickness can reflect the extent and type of parasitic, bacterial, 
and viral infections such as malaria, diarrhoea, and covid 19. Lack of enough 
healthy red blood cells to carry oxygen results in anaemia. Anaemia is a condition 
that occurs due to reduced haemoglobin (Hb) in the blood. Thus, the oxygen-
carrying capacity of the blood is reduced. When the oxygen-carrying capacity is 
reduced, the heart must work harder and faster to deliver the required oxygen to 
the body. If unrecognised, this process could result in serious damage to various 
organs of the body including the cardiovascular system.
Commonly encountered symptoms of anaemia are generalised weakness, 
fatigue, pale appearance, shortness of breath, irritable mood, lack of concentration 
etc. However, if gone untreated, anaemia could result in, precipitate, or aggravate 
heart failure (HF). It could also result in arrhythmias & precipitate heart attacks 
(type 2 myocardial infarction). Anaemia is usually caused by inefficient production 
of red blood cells or the haemoglobin within these cells; by the loss of blood due to 
haemolysis within the circulation or bleeding issues; or due to other chronic medi-
cal conditions like kidney disease or cancer. However, the most common reason for 
anaemia remains iron deficiency (ID) which is critical to produce Hb. ID could exist 
with and without anaemia.
2. Anaemia and iron deficiency in heart failure
Anaemia & ID are common in patients with heart failure. They are associated 
with poor clinical status and worse prognosis [1]. Compared to a 10% prevalence of 
anaemia in the general population it is found in 30% of patients with stable heart 
failure and 50% in those hospitalised, inclusive of heart failure with reduce ejection 
fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) [2–4]. 
Although the pathogenesis of anaemia in heart failure is multifactorial including 
deficiency of vitamin B12 & folate, low erythropoietin production due to renal 
involvement in heart failure, inflammatory components suppressing the production 
of red blood cells and Hb, ID remains one of the major contributors [4–7].
In heart failure it is the ID rather than anaemia that serves as the predictor for 
clinical outcome [8]. impaired quality of life (QoL), reduced exercise capacity, 
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greater morbidity, and mortality all could be predicted by the ID [8–10]. In fact 
ID has been shown to be a strong predictor for patient outcome than anaemia. ID 
without anaemia carries higher risk and poorer outcome compared to an anaemic 
patient without ID [8].
3. Management strategies
Earlier studies have suggested that anaemia is common in HF and carries worse 
prognosis yet measures to increase haemoglobin through red blood cell transfusion 
or erythropoiesis stimulating agents have not shown any beneficial effect in long 
term [4, 11, 12].
Unfortunately, this approach may not only did not improve the outcome in 
patients with HF but were associated with higher risk of adverse effects. This was 
demonstrated in a large study of public discharge database of 596456 patients 
admitted with heart failure [13]. Anaemia was present in 27% patient. The adjusted 
risk mortality was 70% higher in that receiving blood transfusion compared to 10% 
in those who did not. Thus, packed cell transfusion could be beneficial in acute 
anaemic states in heart failure but not in the chronic management.
As regards treatment with erythropoiesis stimulating agents (ESA), a meta-
analysis of 11 earlier studies comprising 794 patients showed benefit in peak oxygen 
consumption, NYHA class, BNP levels and QoL but no significant effect on all-
cause mortality [14]. Subsequently, a large study randomising 2278 patients with 
heart failure and anaemia but no iron deficiency when followed for 28 months did 
not confirm any benefit with the ESA darbopoetin, neither on the primary compos-
ite outcome of death from any cause, hospitalisation or worsening of heart failure. 
The lack of effect was equally present in subgroups as well as on the secondary 
outcomes of fatal MI, stroke, hypertension, and heart failure [15].
As against failure of blood replacement or ESA to demonstrate beneficial effect 
in heart failure, the scenario is different when it comes to treating ID with iron 
replacement. As mentioned earlier, ID is quite common in HF, affecting nearly 50% 
of patients with or without anaemia [8, 16–18]. Iron deficiency in patients with 
HF could be absolute or functional. Total iron is reduced in absolute ID but in the 
functional ID the total body iron is normal or increased but inadequate to fulfil the 
need of body tissues due to sequestration of the storage pools. Studies have shown 
that reversing ID in patient with or without anaemia and HF could improve patient 
outcomes [19], improve QoL and exercise capacity as well as improve depression 
which is also prevalent in patients with HF.
For the treatment of ID, it is important to consider the route of supplementation, 
whether oral of intravenous (IV). The dietary iron is absorbed in the duodenum 
by the enterocytes and subsequently taken up into circulation, bound to transfer-
rin [7]. However, in HF there is gastrointestinal oedema leading to impairment 
of absorption of iron and duodenal iron transport [10]. Also, in HF the hepcidin 
level increases which further reduced the iron levels [20]. Several studies and 
meta-analysis data have studied the role if intravenous iron therapy in patients with 
HF and ID [21], showing its beneficial effect on NYHA class, QoL and 6 min walk 
test. FAIR-HF (Ferinject Assessment in Patients with Iron Deficiency and Chronic 
Heart Failure) randomised 459 patients with ID to IV iron or saline. IV iron therapy 
improved the QoL, 6 min walk test, NYHA level significantly but all-cause mortal-
ity or first hospitalisation remained unchanged [21]. However, a subsequent study 
[22] with similar recruitment criteria conducted on 304 patients but monitored 
for longer duration (52 weeks) showed significant improvement in primary end 
point of 6 min walk test, the benefit sustaining for 1 year. There was improvement 
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in secondary end points NYHA class, QoL, fatigue score and there was reduction 
in the risk of hospitalisation for worsening of HF. However, the all-cause mortality 
did not change. Subsequent studies also showed lower rates of hospitalisation and 
cardiovascular mortality [21].
While advocating IV iron replacement in patients with HF one need be cautious 
with the potential adverse effects of iron overload. As iron is not excreted from 
the body in any form, the mechanism to control iron levels in the body is through 
regulation of its absorption through duodenum [23] which is bypassed when IV 
iron is given. Excess iron can cause cardiomyopathy, widespread tissue damage and 
endothelial dysfunction, all related with adverse cardiovascular outcomes [24]. It is 
therefore critical to prevent iron overload when correcting ID in patients with HF.
4. Conclusion
In this book, we are describing the novel and traditional approaches taken by 
different scientists around the world to relate the status of an erythrocyte (Red 
blood cell) with chronic and acute conditions such as heart failure, which can be 
happening slowly over a period or can happen suddenly.
Heart failure is associated with anaemia about 50% of the patients. Iron defi-
ciency is one of the important caused of anaemia in HF. This is predominantly due 
to lack of absorption of iron from the duodenum that is often inflamed/congested 
in heart failure. Thus, iron replacement is pivotal in the management of HF with ID. 
Intravenous iron Administration of intravenous iron has been proved to be beneficial 
in improving symptoms as well as prognosis in patients with HF and ID.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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